皓元医药(688131) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥299,992,261.46, representing a year-on-year increase of 33.02%[6] - The net profit attributable to shareholders was ¥62,338,825.02, reflecting a growth of 15.06% compared to the same period last year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥58,802,674.97, which is an increase of 9.97% year-on-year[6] - Total operating revenue for Q1 2022 was CNY 299,992,261.46, an increase of 33.0% compared to CNY 225,516,899.25 in Q1 2021[25] - Net profit for Q1 2022 reached CNY 61,771,891.90, representing a 14.5% increase from CNY 54,178,609.59 in Q1 2021[29] - The company reported a total comprehensive income of CNY 61,596,230.95 for Q1 2022, compared to CNY 54,492,549.93 in Q1 2021[31] Research and Development - The total R&D investment amounted to ¥33,470,762.57, marking an increase of 84.54% compared to the previous year[9] - R&D expenses accounted for 11.16% of operating revenue, up by 3.12 percentage points year-on-year[9] - R&D expenses in Q1 2022 amounted to CNY 33,470,762.57, a significant increase of 84.5% compared to CNY 18,137,381.68 in Q1 2021[29] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,500,557,699.50, an increase of 4.86% from the end of the previous year[9] - The equity attributable to shareholders was ¥1,880,280,351.08, reflecting a growth of 3.18% compared to the end of the previous year[9] - The total liabilities increased to CNY 606,710,792.77 in the latest report, up from CNY 548,110,908.44[24] - The company's total assets amounted to approximately CNY 2.50 billion, an increase from CNY 2.38 billion as of December 31, 2021, representing a growth of about 4.9%[19] Cash Flow - The net cash flow from operating activities was negative at -¥3,784,513.39, a decline of 107.29% year-on-year[6] - In Q1 2022, the cash inflow from operating activities was $258,607,901.28, an increase of 14.7% compared to $225,494,489.85 in Q1 2021[36] - The net cash flow from operating activities in Q1 2022 was -$3,784,513.39, a significant decline from $51,880,978.55 in Q1 2021[36] - Cash outflow from investing activities totaled $323,541,199.87 in Q1 2022, compared to $47,300,739.74 in Q1 2021, indicating a substantial increase in investment expenditures[37] - Cash inflow from financing activities was $112,400,000.00 in Q1 2022, with a net cash flow of $100,907,907.55, a recovery from -$15,393,935.25 in Q1 2021[37] Current and Non-Current Assets - The company's cash and cash equivalents decreased to approximately CNY 858.29 million from CNY 1.04 billion, a decline of about 17.3%[19] - Accounts receivable increased significantly to approximately CNY 211.46 million, up from CNY 144.06 million, reflecting a growth of approximately 46.8%[19] - Inventory levels rose to approximately CNY 424.63 million, compared to CNY 352.07 million, indicating an increase of about 20.6%[19] - The company's total current assets amounted to approximately CNY 1.58 billion, slightly down from CNY 1.59 billion, a decrease of about 0.3%[19] - The company’s total non-current assets increased to approximately CNY 921.59 million from CNY 794.06 million, representing a growth of about 16.0%[22] Equity and Earnings - Basic earnings per share for Q1 2022 were CNY 0.84, down from CNY 0.97 in Q1 2021[31] - The total equity attributable to shareholders of the parent company rose to CNY 1,880,280,351.08, compared to CNY 1,822,307,191.98 in the previous period[24] - Deferred income increased to CNY 61,863,956.34 from CNY 59,969,218.96, indicating a growth of 3.2%[24]